Scholar Rock Holding Corporation - Common Stock (SRRK)
44.31
+0.83 (1.91%)
NASDAQ · Last Trade: Mar 3rd, 8:54 PM EST
Detailed Quote
Previous Close
43.48
Open
45.25
Bid
43.60
Ask
47.80
Day's Range
42.56 - 47.50
52 Week Range
22.71 - 49.82
Volume
2,441,369
Market Cap
4.20B
PE Ratio (TTM)
-13.43
EPS (TTM)
-3.3
Dividend & Yield
N/A (N/A)
1 Month Average Volume
999,322
Chart
About Scholar Rock Holding Corporation - Common Stock (SRRK)
Scholar Rock Holding Corp is a biotechnology company focused on developing innovative therapies for the treatment of serious diseases, particularly those related to muscle and neuromuscular disorders. The company's proprietary approach leverages its knowledge of the biology underlying certain conditions to identify and target specific proteins that play a critical role in disease progression. By developing these targeted therapies, Scholar Rock aims to offer new, effective treatment options for patients who currently have limited alternatives. The company is dedicated to advancing its research and clinical programs while fostering collaboration within the scientific and medical communities. Read More
In the release, the first paragraph of the Fourth Quarter and Full Year 2025 Financial Results section, second sentence should read: Net loss per common share was $0.76 for the quarter ended December 31, 2025, compared to $0.61 per common share for the quarter ended December 31, 2024. (instead of Net loss per common share was $0.88 for the quarter ended December 31, 2025, compared to $0.61 per common share for the quarter ended December 31, 2024.) In the Condensed Consolidated Statements of Operations table, Net loss per share, basic and diluted for the Three Months Ended December 31, 2025 should read: $(0.76) (instead of $(0.88)) and the Weighted average common shares outstanding, basic and diluted for the Three Months Ended December 31, 2025 should read: 120,449,524 (instead of 103,087,377).
Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to dramatically improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe, and debilitating neuromuscular diseases by applying its leading platform in myostatin biology to advance musculoskeletal health, today announced that management will participate in the following investor conferences:
Scholar Rock (NASDAQ: SRRK; the “Company”) today announced that the Company granted inducement equity awards covering an aggregate of 114,668 shares of its common stock to seven newly hired employees, consisting of inducement stock options to purchase an aggregate of 64,226 shares of common stock and inducement restricted stock units, covering an aggregate of 50,442 shares of its common stock.
Scholar Rock (NASDAQ: SRRK) today announced that it will report fourth quarter and full year 2025 financial results on Tuesday, March 3, 2026, before the financial markets open.
The Chief Scientific Officer of Scholar Rock Holding Corp has made multiple filings regarding disposals in January 2026, but this should not alarm investors.
Scholar Rock (NASDAQ: SRRK; the “Company”) today announced that the company granted inducement equity awards covering an aggregate of 35,200 shares of its common stock to two newly hired employees, consisting of inducement stock options to purchase an aggregate of 20,400 shares of common stock and inducement restricted stock units, covering an aggregate of 14,800 shares of its common stock.
Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to dramatically improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe, and debilitating neuromuscular diseases by applying its leading platform in myostatin biology to advance musculoskeletal health, today provided a corporate update and highlighted its strategic priorities for 2026.
Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to dramatically improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe, and debilitating neuromuscular diseases by applying its leading platform in myostatin biology to advance musculoskeletal health, today announced that management will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12 at 7:30 a.m. PST (10:30 a.m. EST).
As the final trading days of 2025 approach, the Nasdaq has reached a staggering milestone that has both bulls and bears on edge. According to the latest settlement data released on December 15, 2025, total short interest across the Nasdaq exchange has surged to a record 18.38 billion shares.
Scholar Rock (NASDAQ: SRRK; the “Company”), today announced that the company granted inducement equity awards covering an aggregate of 7,800 shares of its common stock to two newly hired employees, consisting of inducement stock options to purchase an aggregate of 4,457 shares of common stock and inducement restricted stock units, covering an aggregate of 3,343 shares of its common stock.
Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to dramatically improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe, and debilitating neuromuscular diseases by applying its leading platform in myostatin biology to advance musculoskeletal health, today announced that management will participate in the following investor conferences:
Scholar Rock shares jump after the company strengthened its cash runway into 2027 and advanced launch preparations for its lead drug candidate, apitegromab.
